Cogent Biosciences COGT
United StatesHealthcare · BiotechnologyUSD
55.82 USD (+85.2%)
11 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Cogent Biosciences is a clinical-stage biotechnology company developing targeted therapies for diseases with high unmet medical need, focused on oncology and genetic disorders.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Favourable backdrop8.3
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHigh-risk stock suitable only for highly tolerant investors betting on the success of its clinical pipeline; current fundamentals do not justify a buy.
Cogent Biosciences is a development-stage biotech with no revenue, a healthy balance sheet (liquidity 13.57) but significant cash burn (FCF yield -3.56) and a very negative ROE (-109.74), reflecting its pre-commercial stage. The strong stock momentum (+105% over 12 months) suggests market expectations for its pipeline, but the valuation is highly speculative.
The main risk is the failure of its clinical trials or lack of regulatory approval for its drug candidates, which would destroy the company's value as it has no revenue to sustain it.
Context and risks
Development-stage biotech company with no revenue or approved products, implying inherent regulatory and business model risk. Dependence on the success of its clinical trials and FDA approval is the main risk factor, not captured by financial metrics.
Is Cogent Biosciences stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 11.1 | 4.1 | +169% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 55.82 USD, +85.2% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −27.1
- EV / EBITDA
- −12.3
- Price / book
- 11.1
- Market cap
- 5.2B USD
- Enterprise value
- 4.7B USD
Profitability
- ROE
- −109.7%
- ROA
- −43.8%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −186.1M USD
- FCF yield
- −3.6%
Solvency
- Total debt
- 244.3M USD
- Net debt
- −548.0M USD
- Cash
- 792.3M USD
- EBITDA
- −386.5M USD
- Net debt / EBITDA
- 1.42
- Debt / equity
- 45.88
- Current ratio
- 13.57
- Quick ratio
- 13.36
Growth
- EPS (TTM)
- −2.16 USD
- EPS (forward)
- −1.11 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.31
- Analyst consensus
- Strong buy (11)
- Target price
- 55.82 USD
- 52-week range
- 13.78 – 43.73
Recent news
All COGT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Cogent Biosciences
Is Cogent Biosciences stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 55.82 USD, +85.2% versus the price. This is not investment advice.
What score does Cogent Biosciences get on MeridIAn Screener?
It scores 3.5 out of 10, rank 2,030 of 2,130 (better than 4% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Cogent Biosciences worth on the stock market?
Its market capitalisation is 5.2B USD and its enterprise value, debt included, is 4.7B USD.
How much debt does Cogent Biosciences have?
It has more cash than debt: net cash of 548.0M USD.
Does Cogent Biosciences pay a dividend?
It pays no dividend, or almost none.
How has Cogent Biosciences stock performed over the last year?
It has risen 85.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 13.78 and 43.73 USD. Past performance does not guarantee future results.
What do analysts think of Cogent Biosciences?
11 analysts cover it; their average recommendation is “Strong buy” and their average target is 55.82 USD (+85.2% versus the price). It is an estimate, not market data.